# 1 **<u>TITLE PAGE:</u>**

- 2
- 3 Health Economics Assessment of Statin Therapy Initiation Thresholds for
- 4 Atherosclerosis Prevention in China: a Cost-Effectiveness Analysis
- 5
- 6 Authors:
- 7 Tianyu Feng<sup>a</sup>, Xiaolin Zhang<sup>a</sup>, Jiaying Xu<sup>a</sup>, Shang Gao<sup>a</sup>, Xihe Yu<sup>a</sup>
- 8

# 9 Affiliations:

- <sup>a</sup> School of Public Health, Jilin University, Changchun, China;
- 11

## 12 \*Corresponding Author:

- 13 Xihe Yu, Ph.D
- 14 Professor
- 15 School of Public Health
- 16 Jilin University
- 17 Changchun City, Jilin Province, China, 130021
- 18 Tel: 0431-85619446
- 19 E-mail: <u>xhyu@jlu.edu.cn</u>
- 20

## 21 Abstract

**Background:** The latest revised Chinese guidelines for the management of dyslipidemia have lowered the 10-year risk threshold for initiating statins for primary prevention of atherosclerotic heart disease. The aim of this study was to examine the negative impact of different statin treatment initiation thresholds on diabetes in a Chinese population and to assess their health economics value.

27 Methods: In this study, we constructed an event probability-based Microsimulation 28 model to assess the health economics value of statin therapy. The model was based on 29 the Prediction for atherosclerotic cardio-vascular disease (ASCVD) risk in China 30 (China-PAR) and used data from a nationally representative survey and published 31 meta-analysis of the Chinese middle-aged and elderly population as input. We 32 evaluated four different strategies: a 7.5% 10-year risk threshold strategy, a guideline 33 strategy, a 15% 10-year risk threshold strategy, and a 20% 10-year risk threshold 34 strategy. Additionally, we calculated the incremental cost per quality-adjusted life year 35 (QALY) obtained for each strategy to better understand the economics of the various 36 strategies.

37 Result: The incremental cost per QALY for the 10% 10-year risk threshold strategy,
38 compared to the untreated, was \$52,218.75. The incremental cost per QALY for the
39 guideline strategy, compared to the 7.5% 10-year risk threshold strategy, was
40 \$464,614.36. These results were robust in most sensitivity analyses.

41 **Conclusion:** The current 10-year ASCVD risk thresholds used in China's 42 dyslipidemia management guidelines are cost-effective in preventing ASCVD events 43 and should be maintained with the current statin initiation thresholds. Relaxing the 44 initiation threshold as willingness to pay increases would be more cost-effective.

45

46 **Keyword:** Statins; Cost-effectiveness analysis; CHARLS; Risk threshold

### 48 Introduction

49 The disease spectrum in China has undergone significant changes in the last three 50 decades. Cardiovascular diseases have replaced infectious diseases as the leading 51 cause of death[1]. According to statistics, more than 40% of deaths in China are due 52 to cardiovascular diseases, with dyslipidemia being an important risk factor for 53 atherosclerotic cardiovascular disease (ASCVD)[2, 3]. To reduce the risk of major 54 cardiovascular adverse events, clinical guidelines from various countries have 55 recommended the use of statins to manage dyslipidemia[4-6]. A mixture of risk factor 56 rules and absolute risk rules are used in the vast majority of guidelines to determine 57 the conditions that trigger statin intervention, but the threshold for statin initiation 58 recommended in different guidelines varies widely. For example, in the 2016 59 guidelines in China, statins are recommended for primary prevention when a patient 60 has a 10-year ASCVD risk of 10%[4], whereas in Scotland, intervention is triggered 61 when a patient has a 10-year ASCVD risk of 20%[7]. Some countries have set this 62 standard even lower, such as the American Heart Association in its 2018 guideline on 63 blood cholesterol management and the National Institute for Health and Clinical 64 Excellence (NICE) in the UK in the latest version of its revised guideline in 2023, 65 which sets a 10-year incidence of ASCVD of 7.5% as the threshold for triggering 66 statin intervention [5, 6]. An Australian study concluded that a 10-year risk threshold 67 of 15% is more cost-effective than a risk threshold of 5% or 10% for patients with 68 coronary heart disease (CHD) and stroke[8]. It is important to consider the economic 69 value when developing intervention initiation thresholds, especially in developing 70 countries such as China.

71

72 Chinese guidelines for dyslipidemia management recommend initiating statin therapy 73 when a patient's 10-year risk of ASCVD exceeds 10%. However, this threshold 74 remains a subject of debate within the academic community[4, 9]. Economic 75 considerations must be taken into account when setting the threshold. A threshold that

76 is too low may result in increased treatment costs for less vulnerable subgroups 77 without a corresponding increase in health benefits. Conversely, a threshold that is too 78 high may result in undertreatment of patients who could benefit from statins. 79 Although statins effectively control dyslipidemia, they also increase the user's risk of 80 developing diabetes, which significantly affects the occurrence of ASCVD[10-12]. 81 With the highest burden of diabetes in the world[13], China needs to investigate the 82 effect of different statin initiation thresholds on diabetes risk and analyze the 83 cost-effectiveness of statins in preventing ASCVD. This study aims to provide 84 valuable reference information for clinicians and policymakers to develop rational, 85 effective, safe, and economically feasible dyslipidemia management programs. Each 86 country must conduct a cost-effectiveness analysis to determine the optimal threshold 87 for initiating treatment based on its population profile, healthcare level, and economic 88 level.

## 90 Methods

#### 91 Model Structure

92 This study developed a microsimulation model to simulate lifetime ASCVD-related 93 outcomes and costs for individuals aged 40-89 years[14]. The model is based on a 94 modified Markov state model, where individuals transition between health states 95 based on transfer probabilities. Upon entering the model, each individual is assigned 96 parameters such as age, sex, physiological indicators, disease history, and treatment 97 status based on demographic distribution parameters obtained from the 2015 China 98 Health and Retirement Longitudinal Study (CHARLS). The upper age limit of 99 individuals in the model is 89 years old due to the small proportion of the Chinese 100 population aged 90 and above[15]. Individual physiological parameters are updated 101 according to a regression equation as a function of age, as described in Table S5 of the 102 Supplementary Material.

103

104 The probabilities of lethal and nonlethal cardiovascular and stroke events for 105 individuals in the model were calculated from the risk function constructed by 106 China-PAR (Supplementary material Table S6) [9, 16]. The risk of ASCVD is 107 recalculated for individuals in each cycle based on their current physiological 108 parameters, medical history, and treatment status. In the model, individuals are also 109 affected by background mortality. The probability of a diabetic event is based on the 110 annual incidence of diabetes in Chinese adults obtained from previous studies, with 111 the relative risk of statin-induced diabetes calculated and reassigned if the individual 112 is taking statins. Individuals who discontinue treatment will have their baseline 113 incidence rate restored in the next cycle.

114

The model runs on a one-year cycle, with cost and health utility values updated at the end of each cycle. If an individual does not die or reach the modeled age of simulation termination, the simulation proceeds to the next cycle. If an individual dies or reaches

- 118 the age of simulation termination, the simulation stops and costs, health benefits, and
- 119 occurrences of events are recorded throughout the simulation period. The model
- 120 structure is shown in Figure 1 and was implemented using Treeage Pro2019 software.



Figure 1. Structure of the microsimulation model. CHD events include all fatalcoronary events and non-fatal AMI.

124

121

#### 125 Risk of ASCVD events

126 This study used a total risk equation derived from China-PAR to assess the 10-year 127 composite risk of ASCVD events[9, 16]. The 2016 revised Chinese guidelines for the 128 prevention and treatment of dyslipidemia in adults and the Chinese guidelines for 129 cardiovascular disease prevention both recommend using China-PAR as an ASCVD 130 risk assessment tool[4]. The China-PAR risk assessment tool has been widely used in 131 clinical care in China and has been shown to be reliable and valid. China-PAR 132 predicts fatal CHD events (all events caused by acute myocardial infarction (AMI) or 133 other fatal events caused by coronary death), non-fatal AMI, and the 10-year 134 composite probability of fatal and non-fatal stroke. The 10-year probability was 135 converted to a 1-year probability using the DEALE method[17]. The 10-year 136 composite probability of fatal AMI included the 10-year probability of CHD (29.46%) 137 and stroke (70.54%), using their respective proportions of total CHD and stroke 138 events [18]. Patients who survived a CHD event or stroke and did not have a recurrent 139 CHD or stroke event had more than twice the background mortality rate at all 140 follow-up cycles[19]. In the model, individuals who never experienced any ASCVD 141 event were likely to die from background mortality (Supplementary material Tables

142 S2).

143

## 144 **Simulation population**

145 At the beginning of the simulation, the model consisted of 10,000 individuals without 146 a history of ASCVD. Parameters for ASCVD-related risk factors were obtained from 147 the 2015 CHARLS, and all other model inputs are shown in the Supplementary 148 Material (Supplementary material Tables S1, S3 and S4)[20]. To model changes in 149 ASCVD risk factors (mainly HDL-C, TC, SBP, and WC) over time, cross-sectional 150 linear regression was performed using CHARLS data to obtain the relationship 151 between ASCVD risk factors and age (Supplementary material Tables S5) in the 152 China-PAR risk function[17]. Data on the prevalence of diabetes and the increased 153 risk of developing diabetes due to statins at each age were obtained from studies in 154 the literature [21].

155

## 156 Treatment Strategies

157 The guideline treatment-initiation strategy is illustrated in electronic supplementary 158 material Fig. S1. This study discusses statin treatment regimens based on the 2023 159 edition of the Chinese guidelines for lipid management, focusing on the 10-year 160 ASCVD composite risk threshold in the guidelines. The China-PAR risk equation was 161 used to determine patients' 10-year risk of combined ASCVD onset[22]. The 162 guidelines recommend the use of moderate-intensity statins as primary prevention. 163 High-intensity statin therapy was not analyzed because the guidelines suggest that it 164 should be used with caution in the Chinese population[4]. Based on previous studies, 165 it was assumed that 40% of patients would discontinue treatment on their own after 166 one year, and that all patients should adhere to long-term statin treatment[23, 24].

167

168 Since diabetes significantly affects the risk of developing combined ASCVD and 169 statins can slightly increase the risk of developing type 2 diabetes[17, 25], this study

170 focuses on the effect of statin-induced diabetes on the combined risk of ASCVD[26, 171 27]. It was assumed that patients with statin-induced diabetes had good glycemic 172 control and no other comorbidities. In the simulation model, only the effects of 173 statin-induced diabetes on quality of life and costs were included.

174

We analyzed 10-year risks of 7.5%, 10%, and 15% to explore optimal treatment initiation thresholds. These simulated regimens were similar to the strategies in the guidelines, with treatment initiation based on the China-PAR risk function. Treatment-free simulations were also performed.

179

## 180 **Cost and health utility**

181 This study uses the perspective of the Chinese health care system, and costs include 182 only direct medical costs associated with ASCVD, such as statin purchase, inpatient, 183 and outpatient costs (Table 1). Drug costs were obtained based on the 2020 national 184 negotiated prices. We followed the methodology of a similar study and calculated 185 annual drug costs by averaging the lowest winning prices of statins from local 186 government procurement catalogs in each region of China in the first quarter of 2020. 187 Assuming that post-CHD and post-stroke individuals require one outpatient visit per 188 year for the remainder of their lives, we expanded the costs to 2022 using the China 189 Healthcare Component Consumer Price Index.

Parameter	Value	Distribution	Standard	References	
i uluiilotoi	vuide	Distribution	error	References	
Acute disutility				[28]	
Coronary heart disease	0.439	Beta	0.018		
Stroke	0.92	Beta	0.04		
Post-event long-term disutility				[28,29]	
Acute myocardial infarction	0.107	Beta	0.019		
Stroke	0.266	Beta	0.02		
Treatment effect on CHD (OR)	0.7	Log-normal	0.072	[22]	
Treatment effect on stroke (OR)	0.81	Log-normal	0.069	[22]	
Risk of statin-induced diabetes (OR)	1.21	Beta		[30]	
Annual statin treatment costs	1,149.75	Gamma			

Costs (2022 CN¥)	AMI	Stroke		
Hospitalization costs	22,611	13,983	Gamma	[31]
First-year long-term costs	5,255.85	2652	Gamma	[32]
Office visit costs in subsequent	505 07	565	Commo	[22]
years	303.07	303	Gamma	[33]
CHD mortality by age group	Men	Women		[32]
34-44	0.12	0.18	Beta	
45-54	0.21	0.23	Beta	
55-64	0.29	0.27	Beta	
65-74	0.33	0.43	Beta	
75-84	0.48	0.51	Beta	
Stroke mortality by age group	Men	Women		[32]
34-44	0.25	0.18	Beta	
45-54	0.18	0.14	Beta	
55-64	0.12	0.15	Beta	
65-74	0.2	0.2	Beta	
75-84	0.45	0.45	Beta	

190 Table 1. Parameters used in the model.

191

192 QALYs were calculated using age-specific utility weights and event-related negative 193 utility weights, which can be further categorized into acute and long-term negative 194 utility for patients surviving only in the acute phase(Table 1). Age-specific utility 195 weights were derived from the EQ-5D survey of the Chinese general population 196 (Supplementary material Tables S2)[34]. Acute and long-term negative utility weights 197 were extracted from the Global Burden of Disease project and the Chinese EQ-5D 198 survey of patients with chronic diseases [29]. In the baseline case, an annual discount 199 rate of 3% was used[35].

## 200 Intervention Strategy Comparisons

This study evaluates strategies using the incremental cost-benefit ratio (ICER). The cost-benefit ratio of each alternative is calculated, and inferior strategies are removed. China's gross domestic product (GDP) per capita in 2022 (CNY85,700) is used as the cost-effectiveness criterion, and three times the GDP (CNY257,100) is used as the minimum criterion to be cost-effective[36]. In addition, this study employs

206 cost-acceptability curves to illustrate the probability that each strategy is 207 cost-effective at different levels of willingness-to-pay (WTP).

208

### 209 Sensitivity Analysis

We performed one-way and probabilistic sensitivity analyses (PSA) on the model parameters to assess the robustness of the results when the parameters were varied. In the univariate sensitivity analysis, we focused on the effects of statin effectiveness, price, and induction of diabetes on the optimal ASCVD treatment threshold. In PSA, we assessed overall model uncertainty through 1000 randomized simulations.

215

# 216 Model Validation

217 The model used in this study was adapted from an extensively validated 218 Microsimulation model[14, 37], and its internal and external validity were validated 219 based on the model output[38, 39]. Specifically, the internal validity of the model was 220 validated by regression analysis, calculating the expected probabilities of CHD and 221 stroke events for each sex-different age group in the untreated group model against 222 the mean of the simulation results (Supplementary material Figure S2). External 223 validity was verified by comparing simulated ASCVD incidence in the age-sex group 224 (10-year interval) with results from other studies (Supplementary material Table 225 S6)[40].

226

### 228 Results

#### 229 Model calibration and validation

230 Fig S2 in supplementary material displays the internal validation results of the model. 231 The coefficient of determination R2 for the linear regression on the mean of the 232 1-year expected probability of CHD and stroke events and the corresponding 233 simulated values for the untreated group is 0.9278, indicating good internal validity. 234 The simulated stroke incidence in Table 2 aligns well with the prospective study 235 results. China's current published life expectancy per capita is 75.4 years, while the 236 untreated model simulates a life expectancy of 74.9 years, demonstrating good 237 external validity.

238

239

### 240 Clinical Event Results

241 An ASCVD threshold of 7.5% or higher was associated with an estimated 48% of 242 adults being eligible for statin therapy. Strategies with higher ASCVD thresholds were 243 linked to fewer cases of statin-induced diabetes but more CVD events. When applied 244 to the 573 million adults aged 40 to 75 years in China, shifting from a 15% to a 10% 245 ASCVD threshold was associated with an estimated 1,088,716 additional CVD events 246 avoided. Shifting from a 10% to a 7.5% ASCVD threshold was associated with an 247 estimated 687,610 additional CVD events avoided. In contrast, the number of 248 statin-induced diabetes cases was small. This result demonstrates the net effect of 249 statins in reducing cardiovascular events.

250

## 251 Cost-effectiveness analysis

Table 2 presents the base case results of this study. The ICERs for the 15% risk threshold strategy compared to no treatment were \$43,951.82/QALY. The 15% risk threshold strategy is the expansion advantage strategy and was removed from the analysis. The ICERs for the guideline strategy compared to the untreated were

\$52,218.75/QALY. The ICERs for the 7.5% risk threshold strategy compared to the
guideline strategy were \$464,614.36/QALY. Therefore, when using the 3-GDP
criterion, the 7.5% risk threshold strategy was optimal among the three strategies.
When using the 1-GDP criterion, the 10% risk threshold strategy was optimal among
the three strategies.

261

## 262 Sensitivity Analysis

The acceptability curves for the PSA results are displayed in the Figure 2. When using the 3-GDP cost-effectiveness criterion, the guidance strategy has a 32% probability of being optimal, while the 7.5% risk threshold strategy has a 62% probability. When using the 1-GDP criterion, the guidance strategy and the 7.5% risk threshold strategy have equal cost-effectiveness, both with a 30% probability of being optimal. The cost-acceptability curve suggests that the current guideline strategy is more cost-effective than the 7.5% risk threshold strategy when the WTP is below 1-GDP.



270

Figure 2. Acceptability curves were generated using probabilistic sensitivity analysis
results. The horizontal coordinate of the figure represents willingness to pay,
calculated in RMB.

274

275 The tornado plot displays the one-way sensitivity analysis results (figure 3). When all

- 276 parameters are varied within their range of variability, the degree of variation in ICER
- 277 remains within an acceptable range around 1-GDP. Changes in statin prices and the
- 278 risk of statin-induced diabetes have the greatest impact on cost-effectiveness results.



- 280 Figure 3. The tornado plot displays the results of the deterministic sensitivity analysis.
- 281 The price of statins and the risk of statin-induced diabetes had the greatest impact on
- the results.
- 283

ASCVD Risk Threshold, %	Adults Statin Eligible, %	Statin-Induced Diabetes Cases	CVD Events	Mean discounted QALYs	Life Expectancy	Mean discounted costs(CN¥ in 2018)	ICER
No Treatment			0.44	12.17	75.34	49360.91	
15%	39%	0.00695	0.43	12.46	75.63	62236.63	Extended dominance
10%	47%	0.00755	0.43	12.47	75.79	65128.64	52218.75
7.50%	56.00%	0.00745	0.43	12.47	75.81	66866.81	464614.36

284 Table 2. Base-case results of ICERs

285

#### 286 Discussion

287 The primary goal of healthcare systems is to optimize health benefits for the 288 population while minimizing expenditure, particularly in the health economics of 289 preventative therapeutic measures [41]. Statins have been demonstrated to be effective 290 in preventing ASCVD, yet their use has been associated with an increased incidence 291 of diabetes, presenting a challenge for policymakers, healthcare professionals, and 292 patients [42, 43]. Our analysis revealed that using a 7.5% 10-year ASCVD risk as the 293 initiation threshold for statin prevention of ASCVD events was more effective than 294 the current Chinese dyslipidemia management guidelines' recommendation of a 10% 295 10-year ASCVD risk when 3-GDP was used as the criterion. Sensitivity analysis 296 results indicated that the effects of statin sales price and the risk prevention strategy 297 for statin-induced diabetes were more pronounced. Notably, when the price of statins 298 is reduced by 20%, the ICER for the 7.5% threshold strategy will be less than 2-GDP. 299 Overall, our findings suggest that the optimal treatment threshold varies depending on 300 the cost-effectiveness threshold used.

301

302 For adults without cardiovascular disease, the decision to initiate statin therapy should 303 be based on evidence-based evidence and patient preference. When a patient's 304 ASCVD risk reaches the initiation threshold, they may have valid personal reasons for 305 declining statin treatment[44]. In China, financial reasons often lead patients to 306 discontinue treatment. For many lower-income patients without well-established 307 health insurance, the cost is prohibitive[45]. Our one-way sensitivity analysis 308 indicated that statin-induced diabetes has a significant impact on simulation outcomes. 309 Therefore, greater attention should be paid to the glycemic profile of patients taking 310 statins and to their long-term normative glucose monitoring.

311

312 Studies evaluating the economics of statin clinical guidelines in other countries and

313 regions have concluded that the threshold for initiating statin therapy could be further 314 reduced. Pandya et al. assessed the cost-effectiveness of the 2013 ACC/AHA 315 guidelines and alternative risk thresholds for preventing ASCVD events. They 316 determined that the 10-year ASCVD ≥7.5% risk threshold used in the ACC/AHA 317 guidelines was acceptably cost-effective, but that cost-effectiveness would be more 318 pronounced if the 10-year ASCVD risk threshold were further reduced (e.g., to  $\geq 3\%$ 319 or  $\geq 4\%$  [14]. Linda J et al. analyzed current cardiovascular prevention guidelines in 320 Australia and determined that the greatest cost-effectiveness was achieved by 321 recommending statins for individuals with a five-year ASCVD risk greater than 5% or 322 a 10-year ASCVD risk greater than 10%[8]. These studies suggest that more 323 aggressive statin therapy initiation threshold strategies could be further explored. 324 However, because these studies were primarily based on the demographics, healthcare 325 levels, and economic development of developed countries, their results may not be 326 replicable in developing countries like China. Specific statin initiation thresholds 327 should consider the country's willingness to pay.

328

329 Past economic studies of statins have not addressed the impact of diabetes, preventing 330 the analysis from fully reflecting the actual outcomes of statins in preventing ASCVD. 331 However, the risk functions used in past studies are not the parameters currently 332 needed on the front line and are more difficult to obtain, causing the analysis results to 333 deviate somewhat from the actual situation and making it challenging to meet the 334 practical needs of grassroots work. As a result, previous studies have struggled to 335 produce results that provide practical guidance. By improving the model structure and 336 correcting the parameters, this study obtained valuable references for practical clinical 337 work. Cobiac et al. used the average cost-effectiveness ratio of each strategy, rather 338 than ICER, to compare different absolute risk threshold strategies[8]. Jiang et al. 339 analyzed the cost-effectiveness of different risk thresholds using a DEM model based 340 on a national survey [46]. Unlike our study, their study did not include the risk of

statin-induced diabetes in the model, omitting an important factor for ASCVDprevention. Our study addressed this omission.

343

344 Based on this study's results, we recommend that China maintain its current statin 345 initiation threshold. Although our findings suggest that relaxing the threshold would 346 provide greater health economic benefits, clinical event results indicate that it would 347 only marginally reduce the number of ASCVD events. ASCVD is a complex disease 348 influenced by many factors and may not be best addressed solely through statins. 349 Additionally, cost-effectiveness results show that a 7.5% 10-year ASCVD risk 350 threshold would be more cost-effective with increased willingness to pay. However, 351 China's current economic level is not yet comparable to developed countries, and the 352 average Chinese patient's willingness to pay is low. Therefore, Chinese health 353 policymakers should consider relaxing the treatment initiation threshold only after 354 further economic improvement. Finally, hastily lowering the prophylaxis initiation 355 threshold may cause a broken window effect, leading to increased use of other drugs 356 such as anticoagulants and further burdening China's healthcare system.

357

358 Markov model studies tend to have certain limitations. Firstly, Markov cohort models 359 use average probabilities to model individual life courses, making it challenging to 360 obtain more realistic simulation results[47]. In this study, we calculated the absolute 361 ASCVD risk for each individual in the model based on demographic and clinical 362 characteristics from the CHARLS study, allowing treatment decisions to be made 363 based on individual risk. Secondly, a major characteristic of Markov cohort models is 364 their memoryless nature, which also makes it difficult to model the impact of 365 historical events on patient disease outcomes and costs[48]. Microsimulation models 366 can address this by tracking each individual historically and adjusting individual 367 transition probabilities and cost parameters across health states based on historical 368 events.

369

370 This study inevitably has some unavoidable limitations. Firstly, the ASCVD risk 371 function used in this study can only calculate the 10-year combined ASCVD risk, 372 while the risks of developing AMI and stroke cannot be determined separately and 373 must be simulated using a fixed probability level. Secondly, this study focused on the 374 impact of statin-induced diabetes risk on ASCVD prevention and did not explore the 375 health damage and economic loss due to complications in diabetic patients. This is a 376 limitation of our study. Thirdly, previous studies have suggested that statin adherence 377 significantly impacts ASCVD prevention. Due to the lack of data on long-term statin 378 therapy in China, we used studies from other countries to model the impact of poor 379 adherence, which may not accurately reflect the Chinese reality. Finally, although this 380 study modeled the potential risk of statin-induced diabetes, it did not include all 381 potential benefits and risks, such as reduced risk of advanced/aggressive prostate 382 reduced mortality from in-hospital sepsis, and statin-induced cancer, 383 rhabdomyolysis[49-52]. Previous studies have generally considered statin-induced 384 diabetes to be the most significant negative scenario, so the potential factors not 385 included in the analysis likely had minimal impact on this study[46].

When willingness to pay is at 1-GDP, the current 10% 10-year ASCVD risk threshold

# 387 Conclusions

389	used in China's dyslipidemia management guidelines is cost-effective in preventing
390	ASCVD events. Therefore, the current statin initiation threshold should be maintained.
391	However, relaxing the 10-year ASCVD risk threshold would be a better strategy as
392	willingness to pay increases. Changes in statin prices and the risk of statin-induced
393	diabetes have a significant impact on cost-effectiveness outcomes.
394	
395	Abbreviations
396	AMI: Acute myocardial infarction
397	ASCVD: Atherosclerotic cardiovascular disease
398	CHD: Coronary heart disease
399	CHARLS: China Health and Retirement Longitudinal Study
400	China-PAR: Prediction for Atherosclerotic Cardiovascular Disease Risk in China
401	ICER: Incremental cost-benefit ratio
402	PSA: Probabilistic sensitivity analyses
403	QALY: Quality-adjusted life year
404	WTP: Willingness-to-pay
405	
406	Declarations
407	Availability of data and materials
408	The datasets supporting the conclusions are available from the corresponding author
409	(Yu X, xhyu@jlu.edu.cn) on reasonable request.
410	
411	Funding

- 412 No fund was received for this study.
- 413
- 414

415	Consent for publication
416	Not applicable.
417	
418	Author information
419	Authors and Affiliations
420	School of Public Health, Jilin University, Changchun, China
421	Tianyu Feng
422	
423	School of Public Health, Jilin University, Changchun, China
424	Xiaolin Zhang
425	
426	School of Public Health, Jilin University, Changchun, China
427	Jiaying Xua
428	
429	School of Public Health, Jilin University, Changchun, China
430	Shang Gao
431	
432	School of Public Health, Jilin University, Changchun, China
433	Xihe Yu
434	
435	Contributions
436	Tianyu Feng and Xihe Yu design research and draft paper. Data collection and
437	analysis is done by Xiaolin Zhang and Jiaying Xu. Jiaying Xu and Shang Gao revised
438	the article and put forward suggestions. All authors commented on previous versions
439	of the manuscript. All authors read and approved the final manuscript.
440	
441	Acknowledgment
442	Not applicable.

- 443 **Ethics declarations**
- 444 Ethics approval and consent to participate
- 445 Not applicable.
- 446
- 447 **Consent for publication**
- 448 Not applicable.
- 449 **Competing interests**
- 450 The authors declare that they have no competing interests.

### 452 **References**

- 453 1. Wang, L., et al., Prevalence and Treatment of Diabetes in China, 2013-2018.
- 454 JAMA, 2021. 326(24): p. 2498-2506.
- 455 2. Zhou, M., et al., Cause-specific mortality for 240 causes in China during
- 456 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study
- 457 2013. Lancet, 2016. 387(10015): p. 251-72.
- 458 3. Yang, G., et al., Rapid health transition in China, 1990-2010: findings from the
- 459 Global Burden of Disease Study 2010. Lancet, 2013. 381(9882): p. 1987-2015.
- 460 4. Joint committee for guideline, r., 2016 Chinese guidelines for the management of
- 461 dyslipidemia in adults. J Geriatr Cardiol, 2018. 15(1): p. 1-29.
- 462 5. Grundy, S.M., et al., 2018
- 463 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA
- 464 Guideline on the Management of Blood Cholesterol: A Report of the American
- 465 College of Cardiology/American Heart Association Task Force on Clinical Practice
- 466 Guidelines. Circulation, 2019. 139(25): p. e1082-e1143.
- 467 6. guideline CG181, N.I.C.E., Cardiovascular disease: risk assessment and reduction,
- 468 including lipid modification. Methods. 2023, London.
- 469 7. Network, S.I.G., Risk estimation and the prevention of cardiovascular disease.
- 470 2007: Edinburgh: SIGN.
- 471 8. Cobiac, L.J., et al., Improving the cost-effectiveness of cardiovascular disease
- 472 prevention in Australia: a modelling study. BMC Public Health, 2012. 12: p. 398.
- 473 9. Yang, X.L., et al., Risk stratification of atherosclerotic cardiovascular disease in
- 474 Chinese adults. Chronic Dis Transl Med, 2016. 2(2): p. 102-109.
- 475 10. Casula, M., et al., Statin use and risk of new-onset diabetes: A meta-analysis of
- 476 observational studies. Nutr Metab Cardiovasc Dis, 2017. 27(5): p. 396-406.
- 477 11. Mansi, I.A., et al., Association of Statin Therapy Initiation With Diabetes
- 478 Progression: A Retrospective Matched-Cohort Study. JAMA Intern Med, 2021.
- 479 181(12): p. 1562-1574.

- 480 12. Galicia-Garcia, U., et al., Statin Treatment-Induced Development of Type 2
  481 Diabetes: From Clinical Evidence to Mechanistic Insights. Int J Mol Sci, 2020.
  482 21(13).
- 483 13. Li, Y., et al., Prevalence of diabetes recorded in mainland China using 2018
  484 diagnostic criteria from the American Diabetes Association: national cross sectional
  485 study. BMJ, 2020. 369: p. m997.
- 486 14. Pandya, A., et al., Cost-effectiveness of 10-Year Risk Thresholds for Initiation of
- 487 Statin Therapy for Primary Prevention of Cardiovascular Disease. JAMA, 2015.
  488 314(2): p. 142-50.
- 489 15. MD, W. Population pyramids of the World from 1950 to 2100—China 2022.490 2022.
- 491 16. Yang, X., et al., Predicting the 10-Year Risks of Atherosclerotic Cardiovascular
- 492 Disease in Chinese Population: The China-PAR Project (Prediction for ASCVD Risk
  493 in China). Circulation, 2016. 134(19): p. 1430-1440.
- 494 17. Beck, J.R., et al., A convenient approximation of life expectancy (the "DEALE").
- 495 II. Use in medical decision-making. Am J Med, 1982. 73(6): p. 889-97.
- 496 18. Wu, Y., et al., Estimation of 10-year risk of fatal and nonfatal ischemic
  497 cardiovascular diseases in Chinese adults. Circulation, 2006. 114(21): p. 2217-25.
- 498 19. Greving, J.P., et al., Cost-effectiveness of aspirin treatment in the primary
- 499 prevention of cardiovascular disease events in subgroups based on age, gender, and
- 500 varying cardiovascular risk. Circulation, 2008. 117(22): p. 2875-83.
- 501 20. Yang, Z.J., et al., Prevalence of cardiovascular disease risk factor in the Chinese
- 502 population: the 2007-2008 China National Diabetes and Metabolic Disorders Study.
- 503 Eur Heart J, 2012. 33(2): p. 213-20.
- 504 21. Sattar, N., et al., Statins and risk of incident diabetes: a collaborative 505 meta-analysis of randomised statin trials. Lancet, 2010. 375(9716): p. 735-42.
- 506 22. Brugts, J.J., et al., The benefits of statins in people without established 507 cardiovascular disease but with cardiovascular risk factors: meta-analysis of

- 508 randomised controlled trials. BMJ, 2009. 338: p. b2376.
- 509 23. Simons, L.A., et al., Discontinuation rates for use of statins are high. BMJ, 2000.
- 510 321(7268): p. 1084.
- 511 24. Simons, L.A., M. Ortiz, and G. Calcino, Persistence with antihypertensive
- 512 medication: Australia-wide experience, 2004-2006. Med J Aust, 2008. 188(4): p.
- 513 224-7.
- 514 25. Poznyak, A., et al., The Diabetes Mellitus-Atherosclerosis Connection: The Role
- of Lipid and Glucose Metabolism and Chronic Inflammation. Int J Mol Sci, 2020.21(5).
- 517 26. Laakso, M. and J. Kuusisto, Diabetes Secondary to Treatment with Statins. Curr
  518 Diab Rep, 2017. 17(2): p. 10.
- 519 27. Aiman, U., A. Najmi, and R.A. Khan, Statin induced diabetes and its clinical
  520 implications. J Pharmacol Pharmacother, 2014. 5(3): p. 181-5.
- 521 28. Organization, W.H., The global burden of disease: 2004 update. 2008: World522 Health Organization.
- 523 29. Tan, Z., et al., Health-related quality of life as measured with EQ-5D among
- 524 populations with and without specific chronic conditions: a population-based survey
- 525 in Shaanxi Province, China. PLoS One, 2013. 8(7): p. e65958.
- 526 30. Thakker, D., et al., Statin use and the risk of developing diabetes: a network
- 527 meta-analysis. Pharmacoepidemiol Drug Saf, 2016. 25(10): p. 1131-1149.
- 31. Wang, S., et al., Direct medical costs of hospitalizations for cardiovascular
  diseases in Shanghai, China: trends and projections. Medicine (Baltimore), 2015.
  94(20): p. e837.
- 531 32. Gu, D., et al., The Cost-Effectiveness of Low-Cost Essential Antihypertensive
- 532 Medicines for Hypertension Control in China: A Modelling Study. PLoS Med, 2015.
- 533 12(8): p. e1001860.
- 534 33. Zhao, W., et al., Economic burden of obesity-related chronic diseases in Mainland
- 535 China. Obes Rev, 2008. 9 Suppl 1: p. 62-7.

- 536 34. Sun, S., et al., Population health status in China: EQ-5D results, by age, sex and
- 537 socio-economic status, from the National Health Services Survey 2008. Qual Life Res,
- 538 2011. 20(3): p. 309-20.
- 539 35. Wang, X., et al., Guideline for postmarketing Chinese medicine 540 pharmacoeconomic evaluation. Chin J Integr Med, 2015. 21(6): p. 473-80.
- 541 36. Robinson, L.A., et al., Understanding and improving the one and three times GDP
- 542 per capita cost-effectiveness thresholds. Health Policy Plan, 2017. 32(1): p. 141-145.
- 543 37. Bleibler, F., et al., Expected lifetime numbers and costs of fractures in
- 544 postmenopausal women with and without osteoporosis in Germany: a discrete event
- simulation model. BMC Health Serv Res, 2014. 14: p. 284.
- 546 38. Eddy, D.M., et al., Model transparency and validation: a report of the
- 547 ISPOR-SMDM Modeling Good Research Practices Task Force-7. Med Decis Making,
- 548 2012. 32(5): p. 733-43.
- 549 39. Vemer, P., et al., AdViSHE: A Validation-Assessment Tool of Health-Economic
- Models for Decision Makers and Model Users. Pharmacoeconomics, 2016. 34(4): p.349-61.
- 40. Wang, W., et al., Prevalence, Incidence, and Mortality of Stroke in China: Results
- from a Nationwide Population-Based Survey of 480 687 Adults. Circulation, 2017.
  135(8): p. 759-771.
- 41. Boone, J., Basic versus supplementary health insurance: Access to care and therole of cost effectiveness. J Health Econ, 2018. 60: p. 53-74.
- 42. Collins, R., et al., Interpretation of the evidence for the efficacy and safety ofstatin therapy. Lancet, 2016. 388(10059): p. 2532-2561.
- 43. Simic, I. and Z. Reiner, Adverse effects of statins myths and reality. Curr Pharm
  Des, 2015. 21(9): p. 1220-6.
- 44. Rosenbaum, L., Beyond belief--how people feel about taking medications for
  heart disease. N Engl J Med, 2015. 372(2): p. 183-7.
- 563 45. Xiong, X., et al., Impact of universal medical insurance system on the

accessibility of medical service supply and affordability of patients in China. PLoS
One, 2018. 13(3): p. e0193273.

- 46. Jiang, Y. and W. Ni, Economic Evaluation of the 2016 Chinese Guideline and
  Alternative Risk Thresholds of Initiating Statin Therapy for the Management of
  Atherosclerotic Cardiovascular Disease. Pharmacoeconomics, 2019. 37(7): p.
  943-952.
- 47. Caro, J.J., J. Moller, and D. Getsios, Discrete event simulation: the preferred
  technique for health economic evaluations? Value Health, 2010. 13(8): p. 1056-60.
- 48. Hiligsmann, M., et al., Development and validation of a Markov microsimulation
- 573 model for the economic evaluation of treatments in osteoporosis. Value Health, 2009.
- 574 12(5): p. 687-96.
- 575 49. Boudreau, D.M., O. Yu, and J. Johnson, Statin use and cancer risk: a 576 comprehensive review. Expert Opin Drug Saf, 2010. 9(4): p. 603-21.
- 50. Ouellette, D.R., et al., Sepsis outcomes in patients receiving statins prior to hospitalization for sepsis: comparison of in-hospital mortality rates between patients who received atorvastatin and those who received simvastatin. Ann Intensive Care, 2015. 5: p. 9.
- 581 51. Mendes, P., P.G. Robles, and S. Mathur, Statin-induced rhabdomyolysis: a
- 582 comprehensive review of case reports. Physiother Can, 2014. 66(2): p. 124-32.
- 583 52. Ganda, O.P., Statin-induced diabetes: incidence, mechanisms, and implications.
- 584 F1000Res, 2016. 5



The price of statin drugs

The risk of statin-induced diabetes

The cost of long-term treatment of diabetes

CHD event hospitalization costs

The long-term disutility of stroke

Hospitalization costs for stroke

The disutility for Acute Stroke

The disutility for long-term CHD

The disutility for Acute CHD

The Long-term care costs for stroke



EV = ¥44618.21